Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Receives FDA “Complete Response” On Gardasil For Women 27-45

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm also receives complete response to its sBLA for cross-protection.

You may also be interested in...



Gardasil Label Expansion To Women 27-45 Delayed Until 2010, At The Earliest

Merck receives a second “complete response” letter from FDA related to its sBLA to extend indications for the vaccine to older women.

Gardasil Label Expansion To Women 27-45 Delayed Until 2010, At The Earliest

Merck receives a second “complete response” letter from FDA related to its sBLA to extend indications for the vaccine to older women.

Merck Plans Gardasil Campaign Targeting “Mid-adult” Women

FDA clears Pennsylvania manufacturing plant; vaccine sBLAs, including one for Gardasil in “older” women, can proceed.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067983

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel